secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2026-07-01T11:33:29+00:00
Accession:  0001420720-26-000010
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio reports single-dose IBIO-610 achieves 98% Activin E inhibition at 4 weeks in obese NHP study
--------------------------------------------------------------------------------

- Single dose of IBIO-610 reduced active Activin E by 98% at week 4 and 97% at week 8 vs baseline in obese NHPs.
- When combined with semaglutide, IBIO-610 reduced lean mass loss by 73% versus semaglutide alone.
- Data supports potential for infrequent dosing and fat-selective weight loss while preserving lean mass.
- Full dataset to be presented at EASD Annual Meeting in Milan, September 28 – October 2, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000010/0001420720-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000010/ibio-20260701x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer